Sodium‐glucose co‐transporter‐2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
Diabetes Obesity and Metabolism2020Vol. 22(9), pp. 1619–1627
Citations Over TimeTop 1% of 2020 papers
Abstract
High-quality evidence suggests that SGLT2 inhibitors may increase the risk of DKA in patients with type 2 diabetes. The apparent differences in treatment effects among patients of a different age or follow-up were probable, suggesting the advisability of caution in patients with long-term use of SGLT2 inhibitors or in older patients.
Related Papers
- → Frequency and severity of ketoacidosis at diagnosis among childhood type 1 diabetes in Khartoum state, Sudan(2020)13 cited
- → A project identifying potential risk factors leading to diabetic ketoacidosis in patients with type 1 diabetes treated with an insulin pump(2020)2 cited
- Clinical study of correlation between 25-(OH)D and children with type 1 diabetes mellitus and diabetic ketoacidosis(2011)
- The impact of COVID-19 on type 1 diabetes and ketoacidosis incidence in pediatric age(2021)